Novartis net profit jumps 24% to almost $3B


Novartis' (NVS) Q1 net profit leapt 24% to $2.97B and beat consensus of $2.7B, boosted by new drugs such as cancer treatment Afinitor and multiple sclerosis pill Gilenya. Sales in emerging markets, particularly China, also helped lift Novartis' earnings.

Net sales rose 1% to $14.02B, falling short of estimates of $14.25B.

Sales of medicines launched in 2009 or later rose 17% to $4.3B. Gilenya revenue +31% at constant exchange rates to $552M.

Operating profit +22% to $3.5B.

Adjusted profit was flat at $3.21B, or 1.31 a share, with the EPS figure in line.

Novartis reiterated its forecast that 2014 sales will increase by a low to mid-single-digit percentage in constant currencies, and that core operating profit will grow more than sales.

Novartis' results come after the company announced billions of dollars worth of deals in a shake-up of its portfolio earlier this week. (PR)

From other sites
Comments (1)
  • Mike Serebrennik
    , contributor
    Comments (1230) | Send Message
     
    So why is the stock down?
    24 Apr 2014, 11:35 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs